Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

2025 年 10 月 4 日 business, finance, healthcare, medicine, pharmaceuticals

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guidelines in Oncology/NCCN Guidelines for Acute Myeloid Leukemia/AML to include Revuforj (revumenib). Revumenib received a Category 2A recommendation for the treatment of relapsed […]

Doctors Report Rise In Myopia Among Youth, Urge ActionTto Prevent ‘Digital Eye Strain’

2025 年 9 月 24 日 children, health, medicine, public health, technology

With nearly 50 per cent of the population projected to develop near-sightedness or myopia due to prolonged digital device usage, doctors highlighted the need for preventive measures to combat ‘digital eye strain’ – particularly among children. Myopia is a visual condition wherein an individual can see nearby objects clearly, while distant objects appear blurry.